Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 11, 2026, 8:24 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 37 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Metastatic Progressive Castration-resistant Prostate Cancer Clear all
Active, not recruiting Phase 2 Interventional Results available

Sacituzumab Govitecan in Patients With Metastatic Castration-Resistant Prostate Cancer Progressing on Second Generation AR-Directed Therapy

NCT03725761
View directory record Official record
Conditions
Prostate Cancer
Interventions
Sacituzumab Govitecan
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older · Male only
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
3
States / cities
New York, New York • Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Sep 11, 2026, 8:24 AM EDT
Recruiting Phase 1Phase 2 Interventional

An Open-label Dose Escalation and Expansion, Followed by a Phase II Study of Tulmimetostat (DZR123) and JSB462 (Luxdegalutamide) in Patients With Progressive Metastatic Castrate Resistant Prostate Cancer (mCRPC) (TulmiSTAR-01)

NCT07206056
View directory record Official record
Conditions
Progressive Metastatic Castrate Resistant Prostate Cancer
Interventions
Tulmimetostat DL1 QD, Tulmimetostat DL2 QD, Tulmimetostat DL3 QD, Tulmimetostat Doses 1 or 2 QD, Tulmimetostat RP2D QD, JSB462 Dose 1 QD, JSB462 Dose 2 QD, JSB462 QD, Standard of Care (SoC)
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older · Male only
Enrollment
188 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
8
States / cities
Denver, Colorado • Jacksonville, Florida • Atlanta, Georgia + 5 more
Source: ClinicalTrials.gov public record
Updated Aug 20, 2026 · Synced Sep 11, 2026, 8:24 AM EDT
Not listed Phase 1 Interventional

Safety Study of a Radiolabeled Antibody (7E11) in Patients With Progressive Hormone Refractory Prostate Cancer

NCT00441571
View directory record Official record
Conditions
Metastatic Prostate Cancer
Interventions
177Lu-CYT-500
Drug
Lead sponsor
Cytogen Corporation
Industry
Eligibility
18 Years and older · Male only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2007
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 9, 2007 · Synced Sep 11, 2026, 8:24 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional Results available

Phase I Dose-escalation Study of Fractionated 177Lu-PSMA-617 for Progressive Metastatic CRPC

NCT03042468
View directory record Official record
Conditions
Prostate Cancer
Interventions
177Lu-PSMA-617, 68Ga-PSMA-HBED-CC
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years to 99 Years · Male only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2026
U.S. locations
2
States / cities
New Orleans, Louisiana • New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 16, 2025 · Synced Sep 11, 2026, 8:24 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Combining Ipilimumab With Abiraterone Acetate Plus Prednisone in Chemotherapy and Immunotherapy-naïve Patients With Progressive Metastatic Castration-resistant Prostate Cancer

NCT01688492
View directory record Official record
Conditions
Prostate Cancer
Interventions
Ipilimumab
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2026
U.S. locations
3
States / cities
Evanston, Illinois • New York, New York • Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Aug 11, 2026 · Synced Sep 11, 2026, 8:24 AM EDT
Completed Not applicable Interventional

Isolation of Circulating Tumor Cells Using a Novel EMT-Based Capture Method

NCT02025413
View directory record Official record
Conditions
Metastatic Progressive Castration-resistant Prostate Cancer, Metastatic Progressive Breast Cancer
Interventions
Mesenchymal-marker based ferrofluid (N-cadherin or O-cadherin based)
Device
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Dec 19, 2018 · Synced Sep 11, 2026, 8:24 AM EDT
Recruiting Phase 2 Interventional

Treatment of Patients With Progressive mCRPC With 177Lu-PSMA-617

NCT06972628
View directory record Official record
Conditions
Metastatic Castration-Resistant Prostate Cancer, Prostate Cancer Patients With Bone Metastasis, Prostate Cancer (CRPC), Prostate Cancer, Prostate Cancer Metastatic
Interventions
Administering Lutetium-177-PSMA-617 (PLUVICTO)
Drug
Lead sponsor
Ebrahim S Delpassand
Other
Eligibility
18 Years and older · Male only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 14, 2025 · Synced Sep 11, 2026, 8:24 AM EDT
Recruiting Phase 1Phase 2 Interventional

Phase I/II Trial of Pembrolizumab and Androgen-receptor Inhibitor With or Without 225Ac-J591 for Progressive Metastatic Castration Resistant Prostate Cancer

NCT04946370
View directory record Official record
Conditions
Prostate Cancer
Interventions
225Ac-J591, Pembrolizumab, Androgen receptor inhibitor, 68Ga-PSMA-11
Drug · Diagnostic Test
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older · Male only
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2029
U.S. locations
4
States / cities
Boston, Massachusetts • Brooklyn, New York • New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 20, 2026 · Synced Sep 11, 2026, 8:24 AM EDT
Terminated Phase 2 Interventional Results available

Combining CRLX101, a Nanoparticle Camptothecin, With Enzalutamide in People With Progressive Metastatic Castration Resistant Prostate Cancer Following Prior Enzalutamide Treatment

NCT03531827
View directory record Official record
Conditions
Metastatic Castration Resistant Prostate Cancer, Prostate Neoplasms
Interventions
enzalutamide, CRLX101
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Male only
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 11, 2022 · Synced Sep 11, 2026, 8:24 AM EDT
Completed Phase 2 Interventional Results available

I-131-1095 Radioligand Plus Enzalutamide vs Enzalutamide for mCRPC That Progressed During Abiraterone (ARROW).

NCT03939689
View directory record Official record
Conditions
Metastatic Prostate Cancer, Castration-resistant Prostate Cancer, Prostatic Neoplasm, Cancer of the Prostate, Progressive mCRPC
Interventions
I-131-1095, Enzalutamide
Drug
Lead sponsor
Progenics Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older · Male only
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
20
States / cities
Duarte, California • Los Angeles, California • Newport Beach, California + 15 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2025 · Synced Sep 11, 2026, 8:24 AM EDT
Completed Phase 2 Interventional Results available

Determine Effect of Enzalutamide (MDV3100) on the Androgen Signaling Pathway in Correlation With the Anti-tumor Effects of Enzalutamide

NCT01091103
View directory record Official record
Conditions
Metastatic Progressive Castration-resistant Prostate Cancer
Interventions
Enzalutamide
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older · Male only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 22, 2018 · Synced Sep 11, 2026, 8:24 AM EDT
Completed Phase 2 Interventional Results available

Study of TRC105 With Abiraterone and With Enzalutamide in Prostate Cancer Patients Progressing on Therapy

NCT03418324
View directory record Official record
Conditions
Prostate Cancer
Interventions
TRC105, Abiraterone, Enzalutamide
Drug
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years and older · Male only
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Dec 29, 2020 · Synced Sep 11, 2026, 8:24 AM EDT
Not listed Phase 2 Interventional

Tesetaxel in Chemotherapy-naive Patients With Progressive, Castration-resistant Prostate Cancer

NCT01296243
View directory record Official record
Conditions
Prostate Cancer
Interventions
Tesetaxel
Drug
Lead sponsor
Genta Incorporated
Industry
Eligibility
18 Years and older · Male only
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
4
States / cities
Ann Arbor, Michigan • New Brunswick, New Jersey • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 23, 2012 · Synced Sep 11, 2026, 8:24 AM EDT
Completed Phase 2 Interventional

R115777 in Treating Patients With Progressive, Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy

NCT00005848
View directory record Official record
Conditions
Prostate Cancer
Interventions
chemotherapy, tipifarnib
Drug
Lead sponsor
Fox Chase Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2007
U.S. locations
2
States / cities
Cleveland, Ohio • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 10, 2013 · Synced Sep 11, 2026, 8:24 AM EDT
Recruiting Phase 1 Interventional

Phase I Study of 225Ac-J591 Plus 177Lu-PSMA Small Molecule for Progressive Metastatic Castration Resistant Prostate Cancer

NCT04886986
View directory record Official record
Conditions
Prostate Cancer
Interventions
225Ac-J591, 177Lu-PSMA-617, 68Ga-PSMA-11, 177Lu-PSMA-I&T
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years to 99 Years · Male only
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2029
U.S. locations
2
States / cities
Brooklyn, New York • New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 10, 2026 · Synced Sep 11, 2026, 8:24 AM EDT
Active, not recruiting Phase 1 Interventional Results available

Fractionated and Multiple Dose 225Ac-J591 for Progressive mCRPC

NCT04506567
View directory record Official record
Conditions
Prostate Cancer
Interventions
Multiple Dose of 225Ac-J591 at 45 KBq/kg, Multiple Dose of 225Ac-J591 at 55 KBq/kg, Multiple Dose of 225Ac-J591 at 65 KBq/kg, Fractionated Dose of 225Ac-J591 at 45 KBq/kg, Fractionated Dose of 225Ac-J591 at 55 KBq/kg, Fractionated Dose of 225Ac-J591 at 60 KBq/kg, Fractionated Dose of 225Ac-J591 at 65 KBq/kg, Fractionated Dose of 225Ac-J591 at 45 KBq/kg (Prior 177Lu-PSMA-RL), Fractionated Dose of 225Ac-J591 at 50 KBq/kg (Prior 177Lu-PSMA-RL), 68Ga-PSMA-HBED-CC injection
Drug · Diagnostic Test
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years to 99 Years · Male only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
2
States / cities
Brooklyn, New York • New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 18, 2026 · Synced Sep 11, 2026, 8:24 AM EDT
Completed Phase 1 Interventional

Investigating Safety, Tolerability and Efficacy of AZD5363 in Prostate Cancer.

NCT01692262
View directory record Official record
Conditions
Metastatic Castrate-Resistant Prostate Cancer (mCRPC),, Efficacy,, Safety and Tolerability,, Pharmacokinetics,, Pharmacodynamics,, Tumour Response.
Interventions
Intermittent dosing of AZD5363
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older · Male only
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
5
States / cities
Sarasota, Florida • Boston, Massachusetts • Ann Arbor, Michigan + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 18, 2014 · Synced Sep 11, 2026, 8:24 AM EDT
Completed Phase 2 Interventional Results available

A Study of AZD4635 With Durvalumab and With Cabazitaxel and Durvalumab in Patients With mCRPC.

NCT04495179
View directory record Official record
Conditions
Progressive Metastatic Castrate-Resistant Prostate Cancer
Interventions
AZD4635, Durvalumab, Cabazitaxel
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 150 Years · Male only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
5
States / cities
Sacramento, California • Tampa, Florida • Atlanta, Georgia + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 8, 2023 · Synced Sep 11, 2026, 8:24 AM EDT
Completed Phase 1 Interventional

ARN 509 Plus Everolimus in Men With Progressive Metastatic Castration-Resistant Prostate Cancer After Treatment With Abiraterone Acetate

NCT02106507
View directory record Official record
Conditions
Prostate Cancer
Interventions
apalutamide, Everolimus
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 25, 2023 · Synced Sep 11, 2026, 8:24 AM EDT
Active, not recruiting Phase 3 Interventional

Phase 3 Study of Xaluritamig vs Cabazitaxel or Second Androgen Receptor-Directed Therapy in Participants With Progressive Metastatic Castration-Resistant Prostate Cancer (XALute)

NCT06691984
View directory record Official record
Conditions
Metastatic Castration-resistant Prostate Cancer
Interventions
Xaluritamig, Abiraterone, Enzalutamide, Cabazitaxel
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older · Male only
Enrollment
707 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
42
States / cities
Birmingham, Alabama • Duarte, California • Fullerton, California + 32 more
Source: ClinicalTrials.gov public record
Updated May 14, 2026 · Synced Sep 11, 2026, 8:24 AM EDT
Temporarily Not Available No phase listed Expanded access

Expanded Access Treatment with [Lu-177]-PNT2002 for Adult Patients with Prostate-Specific Membrane Antigen (PSMA)-Positive Metastatic Castration-Resistant Prostate Cancer (mCRPC)

NCT06033001
View directory record Official record
Conditions
Castration-Resistant Prostatic Cancer
Interventions
[Lu-177]-PNT2002
Drug
Lead sponsor
Lantheus Medical Imaging
Industry
Eligibility
18 Years and older · Male only
U.S. locations
7
States / cities
Newport Beach, California • Hartford, Connecticut • Jupiter, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Jan 12, 2025 · Synced Sep 11, 2026, 8:24 AM EDT
Completed Phase 2 Interventional

Once-daily Oral Seviteronel in Patients With Castration-Resistant Prostate Cancer Progressing on Enzalutamide or Abiraterone.

NCT02445976
View directory record Official record
Conditions
Prostate Cancer
Interventions
Seviteronel: given orally once daily in 28-day cycles
Drug
Lead sponsor
Innocrin Pharmaceutical
Industry
Eligibility
18 Years and older · Male only
Enrollment
197 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
21
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Los Angeles, California + 17 more
Source: ClinicalTrials.gov public record
Updated Jan 31, 2019 · Synced Sep 11, 2026, 8:24 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Safety, Pharmacokinetic and Proof-of-Concept Study of ARN-509 (Apalutamide) in Castration-Resistant Prostate Cancer (CRPC)

NCT01171898
View directory record Official record
Conditions
Prostate Cancer
Interventions
ARN-509 (Phase 1), ARN-509 (Phase 2)
Drug
Lead sponsor
Aragon Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older · Male only
Enrollment
127 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2025
U.S. locations
15
States / cities
San Diego, California • San Francisco, California • Atlanta, Georgia + 12 more
Source: ClinicalTrials.gov public record
Updated Jun 4, 2026 · Synced Sep 11, 2026, 8:24 AM EDT
Active, not recruiting Phase 3 Interventional Results available

177Lu-PSMA-617 vs. Androgen Receptor-Directed Therapy in the Treatment of Progressive Metastatic Castrate Resistant Prostate Cancer

NCT04689828
View directory record Official record
Conditions
Prostatic Neoplasms
Interventions
177Lu-PSMA-617, 68Ga-PSMA-11, ARDT
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years · Male only
Enrollment
469 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
20
States / cities
Denver, Colorado • Gainesville, Florida • New Orleans, Louisiana + 13 more
Source: ClinicalTrials.gov public record
Updated Sep 10, 2026 · Synced Sep 11, 2026, 8:24 AM EDT